None (BLRX) is a publicly traded company. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer.
Analysis Summary
Balance sheet quality for BLRX: current ratio of 2.0, net cash position of $10.7M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price Performance
| 1 month | -12.98% |
| 3 months | -21.52% |
| Year-to-date | -10.47% |
| 1 year | -34.04% |
| 3 years | -96.92% |
| 5 years | -97.68% |
52-Week Range
| 52-week High | $4.56 |
| 52-week Low | $2.15 |
| Avg Volume (90d) | 40K |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · GOVX · ICU
More sections of BLRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks